Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Scipio Bioscience, a France-based cell sequencing technology developer exploiting University of Geneva research, has collected €6m ($6.5m) in a series A round led by M Ventures, the strategic investment arm of Germany-based drug maker Merck. The round featured public-private partnership High-Tech Gründerfonds (HTGF), venture capital fund Seventure Partners’ Quadrivum I, Financière Arbevel and Investiere. The funding will facilitate the final development phase of Scipio’s RNA-focused sequencing technology ahead of commercial launch in 2022, as well as its marketing and business…
